UCB Announces Positive Phase 3 Data for Psoriasis Treatment
UCB claims its investigational drug bimekizumab demonstrated higher skin clearance rates vs. AbbVie’s blockbuster immunosuppressive drug Humira (adalimumab) in adult patients with moderate-to-severe plaque psoriasis.
The Belgian drugmaker says that bimekizumab, which inhibits inflammatory cytokines, achieved superior clearance rates at week 16.
Additionally, patients who switched to bimekizumab from adalimumab at week 24 saw comparable outcomes to those taking the regimen uninterrupted.
Humira, which earned $4.9 billion in global revenues in 2019, is facing increasing competition from biosimilars.